Evidence map›Paper›PMID 41008294›Full record

ReviewBrain sciences2025

Beyond the Eye: Glaucoma and the Brain.

Marco Zeppieri, Federico Visalli, Mutali Musa, Alessandro Avitabile, Rosa Giglio, Daniele Tognetto, Caterina Gagliano, Fabiana D'Esposito, Francesco Cappellani

Abstract readReview
In one paragraph

Review in Brain sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Marco ZeppieriDepartment of Ophthalmology, University Hospital of Udine, 33100 Udine, Italy.ORCID 0000-0003-0999-5545
Federico VisalliDepartment of Ophthalmology, University of Catania, 95123 Catania, Italy.ORCID 0009-0005-6710-2460
Mutali MusaDepartment of Optometry, University of Benin, Benin 300283, Nigeria.ORCID 0000-0001-7486-8361
Alessandro AvitabileFaculty of Medicine, University of Catania, 95123 Catania, Italy.ORCID 0009-0003-1051-876X
Rosa GiglioDepartment of Medicine, Surgery and Health Sciences, University of Trieste, 34129 Trieste, Italy.ORCID 0000-0001-9755-0786
Daniele TognettoDepartment of Medicine, Surgery and Health Sciences, University of Trieste, 34129 Trieste, Italy.
Caterina GaglianoDepartment of Medicine and Surgery, University of Enna "Kore", 94100 Enna, Italy.ORCID 0000-0001-8424-0068
Fabiana D'EspositoDepartment of Medicine and Surgery, University of Enna "Kore", 94100 Enna, Italy.ORCID 0000-0002-7938-876X
Francesco CappellaniDepartment of Medicine and Surgery, University of Enna "Kore", 94100 Enna, Italy.ORCID 0009-0007-6807-9455

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glaucoma is traditionally classified as an ocular disease characterized by progressive retinal ganglion cell (RGC) loss and optic nerve damage. However, emerging evidence suggests that its pathophysiology may extend beyond the eye, involving trans-synaptic neurodegeneration along the visual pathway and structural changes within central brain regions, including the lateral geniculate nucleus and visual cortex. In this narrative review, we have used the phrase 'brain involvement' to underscore central changes that accompany or follow retinal ganglion cell loss; we have not intended to redefine glaucoma as a primary cerebral disorder. Neuroimaging studies and neurocognitive assessments in adult glaucoma patients, primarily older individuals with primary open-angle glaucoma reveal that glaucoma patients may exhibit alterations in brain connectivity and cortical thinning, aligning it more closely with neurodegenerative disorders such as Alzheimer's and Parkinson's disease. This evolving neurocentric perspective raises important questions regarding shared mechanisms-such as mitochondrial dysfunction, chronic inflammation, and impaired axonal transport-that may link glaucomatous optic neuropathy to central nervous system (CNS) pathology. These insights open promising therapeutic avenues, including the repurposing of neuroprotective and neuroregenerative agents, targeting not only intraocular pressure (IOP) but also broader CNS pathways. Furthermore, neuroimaging biomarkers and brain-targeted interventions may play a future role in diagnosis, prognosis, and individualized treatment. This review synthesizes current evidence supporting glaucoma as a CNS disease, explores the mechanistic overlap with neurodegeneration, and discusses the potential clinical implications of glaucoma within a neuro-ophthalmologic paradigm.

Indexed as

central nervous systemglaucomaneurodegenerationneuroprotectionretinal ganglion cells

Identifiers

PMID41008294
PMCPMC12467791

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.